Global Cardiac Biomarkers Testing Market Size, Status and Forecast 2020-2026
Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart.
Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.
Market Analysis and Insights: Global Cardiac Biomarkers Testing Market
In 2019, the global Cardiac Biomarkers Testing market size was US$ 6872.9 million and it is expected to reach US$ 10710 million by the end of 2026, with a CAGR of 6.5% during 2021-2026.
Global Cardiac Biomarkers Testing Scope and Market Size
Cardiac Biomarkers Testing market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cardiac Biomarkers Testing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Cardiac Biomarkers Testing market is segmented into Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), Others, etc.
Segment by Application, the Cardiac Biomarkers Testing market is segmented into Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others, etc.
Regional and Country-level Analysis
The Cardiac Biomarkers Testing market is analysed and market size information is provided by regions (countries).
The key regions covered in the Cardiac Biomarkers Testing market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.
Cardiac Biomarkers Testing market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Cardiac Biomarkers Testing business, the date to enter into the Cardiac Biomarkers Testing market, Cardiac Biomarkers Testing product introduction, recent developments, etc.
The major vendors include Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories, Inc., Danaher Corporation, ROCHE, Siemens AG, Thermo Fisher Scientific, Inc., PerkinElmer Inc., Tosoh Corporation, etc.
This report focuses on the global Cardiac Biomarkers Testing status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cardiac Biomarkers Testing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
Abbott Laboratories
Becton, Dickinson and Company
BioMerieux
Bio-Rad Laboratories, Inc.
Danaher Corporation
ROCHE
Siemens AG
Thermo Fisher Scientific, Inc.
PerkinElmer Inc.
Tosoh Corporation
Myocardial Muscle Creatine Kinase (CK-MB)
Troponins (T and I)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia-modified Albumin (IMA)
Others
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
To analyze global Cardiac Biomarkers Testing status, future forecast, growth opportunity, key market and key players.
To present the Cardiac Biomarkers Testing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.
In this study, the years considered to estimate the market size of Cardiac Biomarkers Testing are as follows:
History Year: 2015-2019
2019
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.
Market Analysis and Insights: Global Cardiac Biomarkers Testing Market
In 2019, the global Cardiac Biomarkers Testing market size was US$ 6872.9 million and it is expected to reach US$ 10710 million by the end of 2026, with a CAGR of 6.5% during 2021-2026.
Global Cardiac Biomarkers Testing Scope and Market Size
Cardiac Biomarkers Testing market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cardiac Biomarkers Testing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Cardiac Biomarkers Testing market is segmented into Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), Others, etc.
Segment by Application, the Cardiac Biomarkers Testing market is segmented into Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others, etc.
Regional and Country-level Analysis
The Cardiac Biomarkers Testing market is analysed and market size information is provided by regions (countries).
The key regions covered in the Cardiac Biomarkers Testing market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.
Competitive Landscape
and Cardiac Biomarkers Testing Market Share AnalysisCardiac Biomarkers Testing market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Cardiac Biomarkers Testing business, the date to enter into the Cardiac Biomarkers Testing market, Cardiac Biomarkers Testing product introduction, recent developments, etc.
The major vendors include Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories, Inc., Danaher Corporation, ROCHE, Siemens AG, Thermo Fisher Scientific, Inc., PerkinElmer Inc., Tosoh Corporation, etc.
This report focuses on the global Cardiac Biomarkers Testing status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cardiac Biomarkers Testing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
Abbott Laboratories
Becton, Dickinson and Company
BioMerieux
Bio-Rad Laboratories, Inc.
Danaher Corporation
ROCHE
Siemens AG
Thermo Fisher Scientific, Inc.
PerkinElmer Inc.
Tosoh Corporation
Market segment by Type, the product can be split into
Myocardial Muscle Creatine Kinase (CK-MB)
Troponins (T and I)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia-modified Albumin (IMA)
Others
Market segment by Application, split into
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Cardiac Biomarkers Testing status, future forecast, growth opportunity, key market and key players.
To present the Cardiac Biomarkers Testing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.
In this study, the years considered to estimate the market size of Cardiac Biomarkers Testing are as follows:
History Year: 2015-2019
Base Year:
2019Estimated Year:
2020Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
